Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 7/20 | 0.37 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.31 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.31 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.30 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31111510 | 0.80 | BRAF (0.39) | CYP2C9CYP2C19CYP3A4BRAFPSIP1 | |
| SCHEMBL16266543 | 0.80 | BRAF (0.39) | CYP2C9CYP2C19CYP3A4BRAFPSIP1 | |
| SCHEMBL285333 | 0.78 | CYP3A4 (0.63) | CYP2C9CYP2C19CYP3A4BRAFPSIP1 | |
| SCHEMBL12472503 | 0.78 | CYP2C9 (0.63) | CYP2C9CYP2C19CYP3A4BRAFPSIP1 | |
| SCHEMBL28140993 | 0.77 | PSIP1 (0.62) | BRAFPSIP1POLB | |
| SCHEMBL16266453 | 0.74 | KDM4E (0.43) | BRAFPOLB | |
| SCHEMBL28422673 | 0.72 | SLC40A1 (0.50) | CYP2C9CYP2C19BRAFERN1PTGES2 | |
| SCHEMBL21022106 | 0.71 | ERN1 (0.42) | CYP2C9CYP2C19ERN1POLBTLR2 | |
| SCHEMBL31111727 | 0.70 | BRAF (0.39) | CYP2C9BRAFPSIP1 | |
| SCHEMBL12470467 | 0.69 | THRB (0.47) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421761-B2 | Compounds for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10421761-B2 | Compounds for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180099975-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099975-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-9873700-B2 | Compounds for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873700-B2 | Compounds for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3004060-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20140357612-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-12-04 | — | — | US | disclosed |
| US-20140357612-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-12-04 | — | — | US | disclosed |
| WO-2014194127-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014194127-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| US-20140357612-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357612-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP2C9 4724/4885CYP2C19 4598/4885CYP3A4 4658/4885 |
| US-10421761-B2 | Compounds for kinase modulation, and indications therefor | MAP3K20, MAP3K13, MAP3K8 | CYP2C9 4724/4885CYP2C19 4598/4885CYP3A4 4658/4885 |
| US-20180099975-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP2C9 4724/4885CYP2C19 4598/4885CYP3A4 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.